公开(公告)号：US20200317780A1

公开(公告)日：2020-10-08

申请号：US16826102

申请日：2020-03-20

Applicant: Allogene Therapeutics, Inc.

Inventor： Yajin NI ,  Hongxiu NING ,  Janet M. LEE ,  Mark W. LEONARD

IPC: C07K16/28 ,  C12N5/078 ,  C12N15/113

Abstract: Provided herein are improved methods for robust TCR+ cell depletion and production of populations of TCR− cells, which can be beneficial to minimize the GvHD risk in patients receiving allogeneic CAR T cell therapy. Provided herein are methods that increase the efficiency of depleting TCR+ cells from a population of cells in order to significantly reduce any residual levels of TCR+ cells present in cell populations in which expression of endogenous TCR has been reduced or eliminated. Associated kits and cell populations are also provided.

公开(公告)号：US20220241329A1

公开(公告)日：2022-08-04

申请号：US17592105

申请日：2022-02-03

Applicant: Allogene Therapeutics, Inc.

Inventor： Muneeswara Babu MEDI ,  Zhuojin XU ,  Jung S. LEE ,  Yajin NI ,  Mark W. LEONARD

IPC: A61K35/17 ,  A01N1/02 ,  C12N5/0783

Abstract: Provided herein are formulations and drug product processes that can improve cell viability and minimize waste of the manufactured formulated cells for a drug product.

公开(公告)号：US20240277763A1

公开(公告)日：2024-08-22

申请号：US18395996

申请日：2023-12-26

Applicant: ALLOGENE THERAPEUTICS, INC.

Inventor： Thomas Charles PERTEL ,  Barbra Johnson SASU ,  Mark W. LEONARD

IPC: A61K35/17 ,  A61K39/00 ,  A61P35/00 ,  C07K14/705 ,  C07K16/28 ,  C12N5/0783

CPC classification number: A61K35/17 ,  A61P35/00 ,  C07K14/70517 ,  C07K14/70596 ,  C07K16/2803 ,  C12N5/0636 ,  A61K2039/505 ,  C07K2317/76 ,  C07K2319/33 ,  C12N2510/00 ,  C12N2740/15043

Abstract: Provided herein are polynucleotides encoding chimeric antigen receptors (CARs) comprising a CD19 antigen binding domain that specifically birnds to CD19 and is resistant to rituximab binding; and immune cells comprising these CD19-specific CARs, e.g., CAR-T cells. Also provided are methods of making and using these CD19-specific CARs, and immune cells comprising these CD19-specific CARs.

公开(公告)号：US20210062150A1

公开(公告)日：2021-03-04

申请号：US17010707

申请日：2020-09-02

Applicant: Allogene Therapeutics, Inc.

Inventor： Yajin NI ,  Chupei ZHANG ,  Mark W. LEONARD ,  Thomas Charles PERTEL

IPC: C12N5/0783

Abstract: Provided herein are methods for preparing T cells for T cell therapy comprising contacting a cell population at a predetermined cell density, with a concentration of an anti-CD3/CD28 nanomatrix and culturing the cells thereby producing a T cell population comprising an increased percentage of at least one T cell subtype. In some embodiments, the method increases the percentage of stem memory T cells.